People

Figures converted from JPY at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

The People Running This Company

Governance grade: B. Board composition is genuinely independent on paper (4 of 6 directors independent, including two Audit Committee attorneys and a CPA), a founding-family holding company owns ~43% of the stock, and the CEO's compensation leans modestly performance-linked — but the controlling shareholder concentration, low executive equity ownership, and a CEO who personally sets director bonuses inside the Committee's recommendation create real concentration risk that Western minority shareholders should price in.

**Structural snapshot:** Holding company since 2011. Three operating subsidiaries (Teibow Holdings 100%, AlphaTheta 99.9%, JLab 100%). Listed on TSE Prime. 36.2M shares outstanding, 9,416 shareholders. FY2024 board had 14 meetings, 98.8–100% attendance.

1. The People Running This Company

Six directors sit on the Board. Two are executive (the CEO and the CFO), four are independent non-executives (three on the Audit and Supervisory Committee, plus one outside director whose role is advisory). The CEO is young by Japanese standards, the CFO is a career accountant, and three of the four independents are lawyers or CPAs — a governance board built for oversight of a diversified holding company, not for operational stewardship of a single business.

No Results

Ryukichi Iwakiri (CEO) joined Noritsu from DIGITAL HOLDINGS (formerly OPT Inc.), a digital marketing company — not a manufacturing background. He became a director in 2011 (transition to holding company), rose to CEO in 2018 at a relatively young age for a TSE Prime CEO, and has overseen the portfolio transformation: divesting healthcare (JMDC, Doctor-NET), lifestyle (Halmek), and building the current three-manufacturing-subsidiary structure. Results speak: FY2024 revenue $709M with operating EBITDA beating target by 29%, TSR of 233.5 vs TOPIX 175 (cumulative index, base 2020=100).

Ryosuke Yokobari (CFO) is a CPA who joined in 2020, promoted to director/CFO in 2021. Has built Noritsu's capital allocation discipline with the explicit WACC-based framework introduced in MTMP FY30. Serves as director on all three operating subsidiaries.

The four non-executives carry the governance workload: two CPAs + two attorneys. Ota has served 9+ years (long tenure risk); Takada is the lead Nomination/Remuneration chair; Murase is the only female director and the only director with operating manufacturing experience (BANDAI); Machino joined in March 2025 and has environmental law expertise relevant to TCFD/TNFD disclosures.

**One red line:** the *Representative Director and CEO* personally decides individual director base compensation and bonuses, "within limits set by shareholders resolution" and "in accordance with the report" of the Nomination and Remuneration Committee. The Committee *recommends*, but the CEO *decides*. That is not best practice — the Committee should decide directly.

2. What They Get Paid

FY2024 director compensation was $1.71M total across 7 directors. The two executive directors received $1.50M ($0.75M average), non-executives $0.21M ($0.043M average). By global standards, this is modest — and it's the right order of magnitude for a $709M revenue TSE Prime manufacturer.

CEO (Iwakiri) compensation mix: 56% base / 14% bonus / 30% stock. CFO (Yokobari): 61% base / 15% bonus / 24% stock. Stock compensation is restricted-stock-based, with a performance-linked stock option grant to the CEO tied to operating EBITDA (granted in April 2019).

Performance-linked bonus formula weights: 55% operating profit achievement, 40% net profit attributable to owners of parent, 5% sustainability target achievement. Bonus range: 0% to 200% of standard, where standard is ~20–40% of base.

No Results

**FY2024 performance:** both targets beaten handsomely — EBITDA +29%, net profit +87%. At a 200% cap on bonus payout, the CEO effectively maxed his variable comp. This is aligned *and* real.

However, three compensation concerns remain:

Only 5% weight on sustainability — the company disclosed only a token link. For a manufacturer expanding globally with climate disclosures (TCFD, TNFD), this is thin.
No disclosed equity ownership % for the CEO — unlike typical Western proxy disclosures, Noritsu does not publish individual director shareholdings in the integrated report. Stock comp is paid ($0.36M FY24) but the cumulative holdings are opaque.
CEO sets own peer directors' pay within Committee report — structurally questionable.

3. Are They Aligned?

Here is the core tension: Noritsu is effectively family-controlled, but the executives running it are professionals, not family.

Ownership concentration

No Results

**Ownership structure change pending:** As of April 1, 2025, Nishimoto Kosan absorbed THANK Planning; shares (42.21%) transferred to Nishimoto Kosan. Effect is cosmetic at the family level — the Nishimoto family (descendants of founder Kan'ichi Nishimoto) still controls ~49% of the float when combined with Kayo Nishimoto's 5.6% direct stake. Nishimoto Kosan now confirmed as the **controlling shareholder**.

Insider buying/selling

No material insider transactions disclosed in FY2024 filings. Japan's insider disclosure regime is weaker than US Form 4 — the TSE requires major-shareholder reports only at 5%+ thresholds and their changes. The April 2025 Nishimoto Kosan/THANK Planning merger triggered a large-holder report (Report of Possession of a Large Volume, filed April 4, 2025) — a structural reorganization, not a genuine buy/sell transaction.

The CEO receives restricted-stock grants each year (~$0.20M of his $0.70M+ comp, per FY24 mix), so he is accumulating equity — but beginning from a very low base. Noritsu does not publicly disclose individual director shareholdings in the IR.

Dilution

Share count has been stable at 36.19M since at least 2020. 490,314 treasury shares are held (~1.4% of float). Management announced share buybacks as part of MTMP FY30 capital return — dilution risk is effectively zero at current stock comp pace. This is a strong alignment positive.

Capital allocation track record

MTMP FY25 (2021–2025) achieved financial targets one year early. MTMP FY30 (2025–2030) raises the bar: ROE 10%+, payout ratio 50%+, CAGR 10%+. Capital allocation plan is explicit: $865M in growth investment ($666M on M&A in new areas and peripheral businesses, $200M organic), $200M debt repayment, $400M+ shareholder returns. The disclosure quality here is unusual for a $1.5B market cap TSE Prime name — a genuine positive signal.

The only material related-party exposure is through the Nishimoto family holding company structure itself. THANK Planning/Nishimoto Kosan is an unlisted family holding company — there is no public disclosure of whether it charges Noritsu any fees, receives any services, or has intercompany transactions. This is typical of Japanese zaibatsu-style holding structures and should be noted as opaque.

No related-party transactions flagged in the integrated report. The equity-method affiliate Kidswell Bio (23.29%) is a public biotech holding — arms-length.

Skin-in-the-game score

No Results

Overall Skin-in-the-Game Score (/10)

(Hint: the BigValue above pulls the last row where factor = "Overall" — score 6.)

4. Board Quality

No Results

No Results

Heatmap

Missing required column(s): undefined not found in data set.

Governance history

Noritsu has steadily upgraded governance over 14 years: holding company transition (2011), audit & supervisory committee structure (2015), Nomination & Remuneration Committee (2018), Sustainability Promotion Committee (2021), third-party board evaluation (2022), female non-executive director (2024), performance-linked + restricted stock compensation (ongoing). The trajectory is positive; the pace has been deliberate rather than leading.

Risks to flag

**Audit Committee Chair tenure:** Akihisa Ota has served 9 years 9 months. At 10+ years, most governance codes flag the "independent" designation as impaired. Shizu Machino's March 2025 appointment may be intended to manage Ota succession, but no explicit succession timeline has been disclosed.

**Whistleblowing trend:** Reported incidents rose from 0 (2021) to 4 (2022) to 4 (2023) to 8 (2024). Mostly harassment/labor issues (not fraud), and the uptick may reflect *improved reporting culture* rather than worsening behavior — but monitoring is warranted.

**CEO signs off on director pay within Committee report.** Restructure to full Committee decision authority would be best practice.

5. The Verdict

Grade: B

Noritsu Koki is a well-governed founder-controlled Japanese holding company by local standards, with meaningful gaps when benchmarked against US/UK best practice. The CEO has delivered: portfolio restructured, ROE target exceeded early, TSR beat TOPIX by ~33% cumulative through 2024. Disclosure quality on capital allocation, WACC, and MTMP FY30 targets is above average for a $1.5B-market-cap TSE Prime manufacturer.

Strongest positives

Performance delivered and paid. FY24 EBITDA +29% vs target, net profit +87% vs target. CEO bonus earned genuinely.
Explicit capital allocation framework. WACC-driven, ROE 10%+ target, $400M+ shareholder return commitment over 5 years. Rare disclosure quality for a small-cap.
Stable share count. 36.2M shares outstanding for 5+ years, buybacks in plan — no dilution drift.
Independent Audit Committee. 3 of 3 independent, all qualified (CPA + two attorneys). Committee attendance 100%.
Female director appointment (2024) plus second female (2025) push Board to 33% gender diversity — genuinely ahead of TSE Prime average.

Real concerns

Controlling shareholder opacity. Nishimoto Kosan (~42%) is an unlisted family holdco. Minority shareholder protections rely entirely on independent directors.
CEO sets individual director pay within Committee recommendation — structural governance weakness.
Low executive equity ownership. Professional (non-family) executives with modest stock comp from a low base. CEO interests are mostly short-term (bonus) and medium-term (restricted stock vesting), not multi-decade.
Tenure of Audit Committee Chair approaching "impaired independence" threshold at 10 years.
Thin sustainability-linked comp. 5% bonus weight is more ceremonial than substantive.
No board digital/cybersecurity specialist despite expanding software/platform strategy at AlphaTheta.
Whistleblowing incidents doubled YoY in 2024 — worth tracking in 2025.

What would upgrade to A

Replace CEO authority over individual director pay with direct Committee decision.
Add a director with digital platform / cybersecurity expertise.
Disclose individual director shareholdings annually.
Plan and announce Ota succession timeline.
Raise sustainability comp weight to at least 10%.

What would downgrade to C or lower

Related-party transactions discovered between Nishimoto Kosan and Noritsu (fees, services, real estate).
A whistleblower case escalating to regulatory action or public disclosure of fraud/accounting issue.
Buyout-style take-private at a below-market premium led by the founding family (minority-shareholder squeeze).
Concentration of executive decision-making into founder-family hands (currently professional management, which is the key protection).

**Bottom line:** trust management to execute, but read the alignment carefully. The family's 49% stake means minority shareholders are along for the ride — good for long-term discipline, bad if interests diverge. The current CEO has earned the benefit of the doubt through six years of delivery.